HECTD3 negatively regulates host defense against intracellular bacteria by modulation of type I IFN Sep. 7, 2018
Poseida notes data from ongoing phase I study of P-BCMA-101 in relapsed/refractory multiple myeloma Sep. 6, 2018
Phase II TORTUGA trial of filgotinib in ankylosing spondylitis meets primary efficacy endpoint Sep. 6, 2018
RSS